DOCSLIB.ORG

Supplemental Information

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplemental Information Article Supplemental Information INTERNATIONAL STATISTICAL CLASSIFICATION OF DISEASES G020* Meningitis in viral diseases AND RELATED HEALTH PROBLEMS, A852 Arthropod-borne viral classified elsewhere encephalitis, unspecified TENTH REVISION, CANADA CODES USED TO IDENTIFY POTENTIAL G021* Meningitis in mycoses A858 Other specified viral CASES G028* Meningitis in other specified encephalitis infectious and parasitic diseases A86 Unspecified viral encephalitis classified elsewhere A922 Venezuelan equine fever A170 Tuberculous meningitis G030 Nonpyogenic meningitis A923 West Nile virus infection A203 Plague meningitis G031 Chronic meningitis B004 Herpesviral encephalitis A321 Listerial meningitis and G032 Benign recurrent meningitis B011 Varicella encephalitis meningoencephalitis (Mollaret) B020 Zoster encephalitis A390 Meningococcal meningitis G038 Meningitis due to other A870 Enteroviral meningitis specified causes B050 Measles complicated by encephalitis A871 Adenoviral meningitis G039 Meningitis, unspecified B262 Mumps encephalitis A872 Lymphocytic choriomeningitis A811 Subacute sclerosing panencephalitis B582 Toxoplasma A878 Other viral meningitis meningoencephalitis A830 Japanese encephalitis A879 Viral meningitis, unspecified G040 Acute disseminated A831 Western equine encephalitis B003 Herpesviral meningitis encephalitis A832 Eastern equine encephalitis B010 Varicella meningitis G042 Bacterial meningoencephalitis A833 St Louis encephalitis B021 Zoster meningitis and meningomyelitis, not elsewhere A834 Australian encephalitis classified B051 Measles complicated by meningitis A835 California encephalitis G048 Other encephalitis, myelitis and encephalomyelitis B261 Mumps meningitis A838 Other mosquito-borne viral G049 Encephalitis, myelitis and B375 Candidal meningitis encephalitis encephalomyelitis, unspecified B384 Coccidioidomycosis meningitis A839 Mosquito-borne viral encephalitis, unspecified G050* Encephalitis, myelitis and G000 Haemophilus meningitis A840 Far Eastern tick-borne encephalomyelitis in bacterial G001 Pneumococcal meningitis encephalitis (Russian spring-summer diseases classified elsewhere G002 Streptococcal meningitis encephalitis) G05.1* Encephalitis, myelitis and G003 Staphylococcal meningitis A841 Central European tick-borne encephalomyelitis in viral diseases classified elsewhere G008 Other bacterial meningitis encephalitis G052* Encephalitis, myelitis and G009 Bacterial meningitis, A848 Other tick-borne viral encephalitis encephalomyelitis in other infectious unspecified and parasitic diseases classified G00 Bacterial meningitis, not A849 Tick-borne viral encephalitis, elsewhere unspecified elsewhere classified G058* Encephalitis, myelitis and G01 Meningitis in bacterial diseases A850 Enteroviral encephalitis encephalomyelitis in other diseases classified elsewhere A851 Adenoviral encephalitis classified elsewhere PEDIATRICS Volume 140, Number 1, July 2017 SI1 SUPPLEMENTAL TABLE 6 Clinical, Laboratory, and Radiographic Predictors of Adverse Outcomes in Infants With Meningitis (Subgroup of Children Admitted From Home, n = 63) Outcome at Last Follow-up Prognostic Marker, n (%) RR (95% CI) P Seizures in Hospital (21) No Seizures (42) No apparent sequelae 0 18 (43) — <.001 Hearing loss 1 (4.8) 1 (2.4) 2.0 (0.13–30) 1.0 Vision problem 1 (4.8) 0 — .33 Motor problem (spasticity, paresis) 8 (38) 1 (2.4) 16 (2.1–120) <.001 Developmental delay 4 (19) 3 (7.1) 2.7 (0.66–11) .21 Death 4 (19) 0 — .010 CSF protein >5 g/L (6)a CSF protein ≤5 g/L (44)a No apparent sequelae 0 16 (36) — .16 Hearing loss 1 (17) 1 (2.3) 7.3 (0.52–100) .23 Vision problem 0 1 (2.3) — 1.0 Motor problem (spasticity, paresis) 3 (50) 6 (14) 3.7 (1.2–11) .063 Developmental delay 1 (17) 2 (4.5) 3.7 (0.39–35) .32 Death 1 (17) 1 (2.3) 7.3 (0.52–100) .23 Hydrocephalus on neuroimaging (10) No hydrocephalus (53) No apparent sequelae 0 18 (34) — .050 Hearing loss 1 (10) 1 (1.9) 5.3 (0.36–78) .29 Vision problem 0 1 (1.9) — 1.0 Motor problem (spasticity, paresis) 4 (40) 5 (9.4) 4.2 (1.4–13) .029 Developmental delay 2 (20) 5 (9.4) 2.1 (0.48–9.4) .31 Death 1 (10) 3 (5.7) 1.7 (0.20–15) .51 Numbers in table represent n (%) or RR (95% CI). RR, relative risk. —, not applicable. a Data missing for CSF protein for 13 patients (n = 50). SUPPLEMENTAL TABLE 7 Clinical, Laboratory, and Radiographic Predictors of Adverse Outcomes in Infants With Meningitis (Subgroup of Children Remaining in Hospital Since Birth, n = 50) Outcome at Last Follow-up Prognostic Marker, n (%) RR (95% CI) P Seizures in Hospital (20) No Seizures (30) No apparent sequelae 4 (20) 7 (23) 0.86 (0.29–2.6) 1.0 Hearing loss 3 (15) 0 — .058 Vision problem 0 0 — 1.0 Motor problem (spasticity, paresis) 4 (20) 6 (20) 1.0 (0.32–3.1) 1.0 Developmental delay 4 (20) 1 (3.3) 6.0 (0.72–50) .14 Death 3 (15) 1 (3.3) 4.5 (0.50–40) .29 CSF protein >5 g/L (n = 11)a CSF protein ≤5 g/L (n = 28)a No apparent sequelae 2 (18) 6 (21) 0.85 (0.20–3.6) 1.0 Hearing loss 1 (9.1) 0 — .28 Vision problem 0 0 — 1.0 Motor problem (spasticity, paresis) 3 (27) 3 (11) 2.5 (0.60–11) .32 Developmental delay 2 (18) 1 (3.6) 5.1 (0.51–51) .19 Death 1 (9.1) 2 (7.1) 1.3 (0.13–13) 1.0 Hydrocephalus on neuroimaging (14) No hydrocephalus (36) No apparent sequelae 3 (21) 8 (22) 0.96 (0.30–3.1) 1.0 Hearing loss 2 (14) 1 (2.8) 5.1 (0.51–52) .19 Vision problem 0 0 — 1.0 Motor problem (spasticity, paresis) 6 (43) 4 (11) 3.9 (1.3–12) .020 Developmental delay 1 (7.1) 4 (11) 0.64 (0.079–5.3) 1.0 Death 1 (7.1) 3 (8.3) 0.85 (0.097–7.6) 1.0 Numbers in table represent n (%) or RR (95% CI). RR, relative risk. —, not applicable. a Data missing for CSF protein for 11 patients (n = 39). SI2 OUCHENIR et al.
Load more

Recommended publications
  • ICD10 Diagnoses FY2018 AHD.Com
    ICD10 Diagnoses FY2018 AHD.com A020 Salmonella enteritis A5217 General paresis B372 Candidiasis of skin and nail A040 Enteropathogenic Escherichia coli A523 Neurosyphilis, unspecified B373 Candidiasis of vulva and vagina infection A528 Late syphilis, latent B3741 Candidal cystitis and urethritis A044 Other intestinal Escherichia coli A530 Latent syphilis, unspecified as early or B3749 Other urogenital candidiasis infections late B376 Candidal endocarditis A045 Campylobacter enteritis A539 Syphilis, unspecified B377 Candidal sepsis A046 Enteritis due to Yersinia enterocolitica A599 Trichomoniasis, unspecified B3781 Candidal esophagitis A047 Enterocolitis due to Clostridium difficile A6000 Herpesviral infection of urogenital B3789 Other sites of candidiasis A048 Other specified bacterial intestinal system, unspecified B379 Candidiasis, unspecified infections A6002 Herpesviral infection of other male B380 Acute pulmonary coccidioidomycosis A049 Bacterial intestinal infection, genital organs B381 Chronic pulmonary coccidioidomycosis unspecified A630 Anogenital (venereal) warts B382 Pulmonary coccidioidomycosis, A059 Bacterial foodborne intoxication, A6920 Lyme disease, unspecified unspecified unspecified A7740 Ehrlichiosis, unspecified B387 Disseminated coccidioidomycosis A080 Rotaviral enteritis A7749 Other ehrlichiosis B389 Coccidioidomycosis, unspecified A0811 Acute gastroenteropathy due to A879 Viral meningitis, unspecified B399 Histoplasmosis, unspecified Norwalk agent A938 Other specified arthropod-borne viral B440 Invasive pulmonary
    [Show full text]
  • Educational Achievement and Economic Self-Sufficiency in Adults After Childhood Bacterial Meningitis
    1 Supplementary Online Content Roed C, Omland LH, Skinhoj P, Rothman KJ, Sorensen HT, Obel N. Educational achievement and economic self-sufficiency in adults after childhood bacterial meningitis. JAMA. doi:10.1001/jama.2013.3792 Appendix 1. Description of Registries Appendix 2. Diagnosis Codes for Intrauterine and Birth Asphyxia or Chromosomal Abnormalities Appendix 3. Diagnosis Codes for Meningococcal, Pneumococcal, Or H influenzae Meningitis Appendix 4. Diagnosis Codes for Neuroinfections Other Than Bacterial Meningitis eTable 1. Number of Events in the Study Population and Total Observation Time eTable 2. Estimated Prevalence at Age 35 of Vocational Education, High School, Higher Education, Economic Self‐sufficiency and Disability pension Among Meningitis Patients, Members of the Population Comparison Cohorts, and Their Siblings Without Neonatal Morbidity eFigure 1. Cumulative Incidence of Having Been Economically Self‐sufficient for a Year and of Receiving Disability Pension in the Meningococcal, Pneumococcal and H. influenzae Meningitis Patients (Black), Members of the Population Comparison Cohort (Red), Full Siblings of Patients (Green) and Siblings of Members of the Population Comparison Cohort (Blue) eFigure 2. Cumulative Incidence of Vocational Education, High School and Higher Education for Meningococcal, Pneumococcal and H. influenzae Meningitis Patients (Black), Members of the Population Comparison Cohort (Red), Full Siblings of Patients (Green) and Full Siblings of Members of the Population Comparison Cohort (Blue) Born Before 1980 eFigure 3. Cumulative Incidence of Vocational Education, High School and Higher Education for Meningococcal, Pneumococcal and H. influenzae Meningitis Patients (Black), Members of the Population Comparison Cohort (Red), Full Siblings of Patients (Green) and Full Siblings of Members of the Population Comparison Cohort (Blue) Born After 1980 This supplementary material has been provided by the authors to give readers additional information about their work.
    [Show full text]
  • Neuropsychological Testing
    Medical Coverage Policy Effective Date ............................................. 8/15/2021 Next Review Date ....................................... 8/15/2022 Coverage Policy Number .................................. 0258 Neuropsychological Testing Table of Contents Related Coverage Resources Overview .............................................................. 1 Attention-Deficit/Hyperactivity Disorder: Assessment Coverage Policy ................................................... 1 and Treatment General Background ............................................ 2 Autism Spectrum Disorder/Pervasive Developmental Medicare Coverage Determinations .................. 15 Disorders: Assessment and Treatment Coding/Billing Information .................................. 16 Cognitive Rehabilitation Lyme Disease Treatment— Antibiotic Treatment References ........................................................ 28 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary
    [Show full text]
  • Academy of Medical Sciences of Ukraine L. V. Gromashevskiy
    Academy of Medical Sciences of Ukraine L. V. Gromashevskiy Institute of Epidemiology and Infektious Diseases Panasiuk Olena Leonidivna ETHIOPATHOGENETIC THERAPY OF HERPES VIRUS INFECTION WITH THE USE OF PROTEFLAZID 14.01.13 — Infektious Diseases Kyiv — 2007 TABLE OF CONTENTS LIST OF ABBREVIATIONS USED INTRODUCTION CHAPTER 1 PRESSING ISSUES OF TREATMENT OF HERPES VIRUS INFECTIONS 1.2. Main principles of treatment of patients with herpes virus infections CHAPTER 2 MATERIALS AND STUDY METHODS 2.1. Characteristic of examined patients 2.2. Characteristic of study drug and treatment methods 2.3. Study design 2.3.1. Subjects enrollment and discontinuation criteria 2.3.2. Principles and algorithm of subjects grouping 2.3.3. Assessment of therapy efficacy 2.4. Study methods 2.4.1. Clinical method 2.4.2. Special study methods 2.4.3. Statistical method CHAPTER 3 ETHIOPATHOGENETIC THERAPY OF HERPES VIRUS INFECTION WITH THE USE OF PROTEFLAZID 3.1. Clinical efficacy of Proteflazid 3.2. Adverse effects of therapy with Proteflazid 3.3. Interferon inducing and immunomodulatory activity of Proteflazid in subjects with herpes virus infection 3.3.1. Immunomodulatory activity of Proteflazid 3.3.2. Interferon inducing properties of Proteflazid CHAPTER 4 LONG-TERM RESULTS OF TREATMENT OF HERPES VIRUS INFECTION 4.1. Anti-relapse efficacy of Proteflazid CONCLUSIONS PRACTICAL GUIDELINES REFERENCES List of abbreviations used NK (CD16) — natural killer cells NSE — neurospecific enolase ME — meningoencerebritis ANAD — acyclic nucleoside antiviral drugs AB — antibody
    [Show full text]
  • SNF Mobility Model: ICD-10 HCC Crosswalk, V. 3.0.1
    The mapping below corresponds to NQF #2634 and NQF #2636. HCC # ICD-10 Code ICD-10 Code Category This is a filter ceThis is a filter cellThis is a filter cell 3 A0101 Typhoid meningitis 3 A0221 Salmonella meningitis 3 A066 Amebic brain abscess 3 A170 Tuberculous meningitis 3 A171 Meningeal tuberculoma 3 A1781 Tuberculoma of brain and spinal cord 3 A1782 Tuberculous meningoencephalitis 3 A1783 Tuberculous neuritis 3 A1789 Other tuberculosis of nervous system 3 A179 Tuberculosis of nervous system, unspecified 3 A203 Plague meningitis 3 A2781 Aseptic meningitis in leptospirosis 3 A3211 Listerial meningitis 3 A3212 Listerial meningoencephalitis 3 A34 Obstetrical tetanus 3 A35 Other tetanus 3 A390 Meningococcal meningitis 3 A3981 Meningococcal encephalitis 3 A4281 Actinomycotic meningitis 3 A4282 Actinomycotic encephalitis 3 A5040 Late congenital neurosyphilis, unspecified 3 A5041 Late congenital syphilitic meningitis 3 A5042 Late congenital syphilitic encephalitis 3 A5043 Late congenital syphilitic polyneuropathy 3 A5044 Late congenital syphilitic optic nerve atrophy 3 A5045 Juvenile general paresis 3 A5049 Other late congenital neurosyphilis 3 A5141 Secondary syphilitic meningitis 3 A5210 Symptomatic neurosyphilis, unspecified 3 A5211 Tabes dorsalis 3 A5212 Other cerebrospinal syphilis 3 A5213 Late syphilitic meningitis 3 A5214 Late syphilitic encephalitis 3 A5215 Late syphilitic neuropathy 3 A5216 Charcot's arthropathy (tabetic) 3 A5217 General paresis 3 A5219 Other symptomatic neurosyphilis 3 A522 Asymptomatic neurosyphilis 3 A523 Neurosyphilis,
    [Show full text]
  • 30-Year Trends in Admission
    Iro, M. A., Sadarangani, M., Goldacre, R., Nickless, A., Pollard, A., & Goldacre, M. J. (2017). 30-year trends in admission rates for encephalitis in children in England and effect of improved diagnostics and measles-mumps-rubella vaccination: a population-based observational study. The Lancet Infectious Diseases. https://doi.org/10.1016/S1473-3099(17)30114-7 Peer reviewed version License (if available): CC BY-NC-ND Link to published version (if available): 10.1016/S1473-3099(17)30114-7 Link to publication record in Explore Bristol Research PDF-document This is the accepted author manuscript (AAM). The final published version (version of record) is available online via Elsevier at https://doi.org/10.1016/S1473-3099(17)30114-7 . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ Thirty-year trends in admission rates for childhood encephalitis in England and impact of improved diagnostics and measles and mumps vaccination– a population based observational study Mildred A Iro (MBBS) 1, Manish Sadarangani (DPhil) 1,2, Raphael Goldacre (MSc)3, Alecia Nickless (MSc) 4, Prof Andrew J Pollard* (FMedSci) 1, Prof Michael J Goldacre* (FFPH) 3 1Oxford Vaccine Group, Department of Paediatrics, University of Oxford, and the NIHR Oxford Biomedical
    [Show full text]
  • Supplementary Appendix
    Supplementary appendix Sipilä PN, Heikkilä N, Lindbohm JV, Hakulinen C, Vahtera J, Elovainio M, Suominen S, Väänänen A, Koskinen A, Nyberg ST, Pentti J, Strandberg TE, Kivimäki M. Hospital-treated infectious diseases and the risk of incident dementia: multicohort study with replication in the UK Biobank CONTENTS eFigure 1. Selection of participants in the study............................................................................... 2 eMethods 1. Study cohorts and data collection ................................................................................ 3 The Finnish Public Sector study (FPS)......................................................................................... 3 The Health and Social Support study (HeSSup) ........................................................................... 4 The Still Working study (STW) ................................................................................................... 5 The UK Biobank ......................................................................................................................... 5 eMethods 2. Proportionality of hazards ........................................................................................... 7 eFigure 2. Visualisation of hazard ratios over time using exponentiated scaled Schoenfeld residuals ....................................................................................................................................................... 8 eFigure 3. Dementia follow-up .....................................................................................................
    [Show full text]
  • New Emergency Room Requirement for Hospital and Autopay List of Diagnosis Codes
    Provider update New emergency room requirement for hospitals Dell Children’s Health Plan reviewed our emergency room (ER) claims data and identified numerous reimbursements for services with diagnoses that are not indicative of urgent or emergent conditions. As a managed care organization, we promote the provision of services in the most appropriate setting and reinforce the need for members to coordinate care with their PCP unless the injury or sudden onset of illness requires immediate medical attention. Effective on or after August 1, 2020, for nonparticipating hospitals and on or after October 1, 2020, for participating hospitals, Dell Children’s Health Plan will only process an ER claim for a hospital as emergent and reimburse at the applicable contracted rate or valid out‐ of‐network Medicaid fee‐for‐service rate when a diagnosis from a designated auto‐pay list is billed as the primary diagnosis on the claim. If the primary diagnosis is not on the auto‐pay list, the provider must submit medical records with the claim. Upon receipt, the claim and records will be reviewed by a prudent layperson standard to determine if the presenting symptoms qualify the patient’s condition as emergent. If the reviewer confirms the visit was emergent, according to the prudent layperson criteria, the claim will pay at the applicable contracted rate or valid out‐of‐network Medicaid fee‐for‐service rate. If it is determined to be nonemergent, the claim will pay a triage fee. In the event a claim from a hospital is submitted without a diagnosis from the auto‐pay list as the primary diagnosis and no medical records are attached, the claim for the ER visit will automatically pay a triage fee.
    [Show full text]
  • Diagnosis One To
    Diagnosis One-to-One I9cm I9 Long Desc I10cm I10 Long Desc 0010 Cholera due to vibrio cholerae A000 Cholera due to Vibrio cholerae 01, biovar cholerae 0011 Cholera due to vibrio cholerae el tor A001 Cholera due to Vibrio cholerae 01, biovar eltor 0019 Cholera, unspecified A009 Cholera, unspecified 0021 Paratyphoid fever A A011 Paratyphoid fever A 0022 Paratyphoid fever B A012 Paratyphoid fever B 0023 Paratyphoid fever C A013 Paratyphoid fever C 0029 Paratyphoid fever, unspecified A014 Paratyphoid fever, unspecified 0030 Salmonella gastroenteritis A020 Salmonella enteritis 0031 Salmonella septicemia A021 Salmonella sepsis 00320 Localized salmonella infection, unspecified A0220 Localized salmonella infection, unspecified 00321 Salmonella meningitis A0221 Salmonella meningitis 00322 Salmonella pneumonia A0222 Salmonella pneumonia 00323 Salmonella arthritis A0223 Salmonella arthritis 00324 Salmonella osteomyelitis A0224 Salmonella osteomyelitis 0038 Other specified salmonella infections A028 Other specified salmonella infections 0039 Salmonella infection, unspecified A029 Salmonella infection, unspecified 0040 Shigella dysenteriae A030 Shigellosis due to Shigella dysenteriae 0041 Shigella flexneri A031 Shigellosis due to Shigella flexneri 0042 Shigella boydii A032 Shigellosis due to Shigella boydii 0043 Shigella sonnei A033 Shigellosis due to Shigella sonnei 0048 Other specified shigella infections A038 Other shigellosis 0049 Shigellosis, unspecified A039 Shigellosis, unspecified 0050 Staphylococcal food poisoning A050 Foodborne staphylococcal
    [Show full text]
  • BQI Icare HIV/AIDS
    RESOURCE AND PATIENT MANAGEMENT SYSTEM iCare Population Management GUI (BQI) HIV/AIDS Management User Manual Version 2.6 July 2017 Office of Information Technology (OIT) Division of Information Technology iCare Population Management GUI (BQI) Version 2.6 Table of Contents 1.0 Introduction ......................................................................................................... 1 1.1 Key Functional Features .......................................................................... 1 1.2 Sensitive Patient Data ............................................................................. 2 2.0 Patient Management ........................................................................................... 3 2.1 Data Specifically Related to HIV/AIDS ..................................................... 3 2.2 Search for and View a Patient Record ..................................................... 6 2.2.1 Using a Panel ........................................................................................ 6 2.2.2 Using Quick Search ............................................................................... 7 2.3 Displaying Care Management as Default Tab ......................................... 8 2.4 Add/Edit Care Management Data ............................................................ 8 2.4.1 Entering Data on the General Area ....................................................... 9 2.4.2 Entering Data on the Partner Notification Area .................................... 11 2.4.3 Entering Data on the Antiretroviral
    [Show full text]
  • ITDRD Book.Book
    2 0 2 DESK REFERENCE 1 optum360coding.com Seamless shopping starts here. Diagnoses ICD-10-CM for Reference Desk Coders’ Coders’ Desk Reference The redesigned optum360coding.com offers new conveniences and the same great coding resources you’ve always trusted for a convenient, seamless shopping experience. for ICD-10-CM Diagnoses Device-friendly shopping Product information at Clinical descriptions with answers to your your fingertips Effortlessly view our new website on toughest ICD-10-CM coding questions any device — desktop, tablet or Find product details and features — smartphone — optum360coding.com including item number, ISBN number and is with you wherever you go. availability date — quickly and easily. Intuitive product organization Streamlined checkout Optum360 coding products are View and edit your cart, ship to multiple organized by category so you can find recipients, add payment information, what you need quickly and easily. assign a PO number and complete your purchase — all on one page. Sign in to check out View all your account Signing in prior to checkout ensures information your online and offline transactions are seamlessly linked to the same account for Get immediate access to your order and your convenience. Don’t have an online invoice history, track shipments, renew a account? It’s easy to create one — visit product, create a wish list or update your optum360coding.com/register. contact information. Visit optum360coding.com © 2020 Optum360, LLC. All rights reserved. WF2305592 04/20 SAMPLE ITDRD21/ITDRD Made in the USA
    [Show full text]
  • Assessment of the Demyelinating Process
    Wiadomości Lekarskie, VOLUME LXXIV, ISSUE 3 PART 1, MARCH 2021 © Aluna Publishing ORIGINAL ARTICLE ASSESSMENT OF THE DEMYELINATING PROCESS ACTIVITY IN PATIENTS WITH HERPESVIRAL MENINGITIS AND MENINGOENCEPHALITIS BASED ON THE LEVEL OF MYELIN BASIC PROTEIN (MBP) IN THE CEREBROSPINAL FLUID DOI: 10.36740/WLek202103124 Anton V. Sokhan1, Yaroslava I. Burma1, Volodimir V. Pavlov2, Oleksandr O. Goidenko2, Larisa I. Markush2, Hanna O. Spitsyna3, Liudmyla V. Kolesnyk4 1 KHARKIV NATIONAL MEDICAL UNIVERSITY, KHARKIV, UKRAINE 2 KHARKIV REGIONAL CLINICAL INFECTIOUS DISEASES HOSPITAL, KHARKIV, UKRAINE 3 NATIONAL AEROSPACE UNIVERSITY «KHARKIV AVIATION INSTITUTE», KHARKIV, UKRAINE 4 KHARKIV NATIONAL UNIVERSITY OF RADIO ELECTRONICS, KHARKIV, UKRAINE ABSTRACT The aim: To study the peculiarities of demyelination by detection of changes in the levels of myelin basic protein (MBP) in CSF of patients with acute herpesviral meningitis (M) and meningoencephalitis (ME). Materials and methods: A total of 136 CSF samples from 68 patients with herpesviral M and ME were collected. The control group consisted of patients with acute respiratory infection and meningismus. MBP level in CSF was identified at the admission and after 10-12 days of treatment. Analysis of MBP concentrations in CSF was performed using an enzyme immunoassay. Results: Examination of patients on the first day of hospitalization showed the presence of a significant increase of MBP in the CSF in all patients with viral M/ME compared with the indicators of the comparison group (р<0.01). In all groups of patients with ME, the level of MBP in CSF was significantly higher than the indicators of comparison group and M groups of the suitable etiology of the disease (p<0.01).
    [Show full text]